A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects With Advanced Liver Disease

Trial Profile

A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects With Advanced Liver Disease

Completed
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Daclatasvir (Primary) ; Simeprevir (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 Sep 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network.
    • 30 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top